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Abstract
There is a growing body of evidence implicating aber-
rant circadian clock expression in the development of
cancer. Based on our initial experiments identifying a
putative interaction between BRCA1 and the clock
proteins Per1 and Per2, as well as the reported involve-
ment of the circadian clock in the development of
cancer, we have performed an expression analysis of
the circadian clock genes Per1 and Per2 in both spo-
radic and familial primary breast tumors and normal
breast tissues using real-time polymerase chain reac-
tion. Significantly decreased levels of Per1 were ob-
served between sporadic tumors and normal samples
(P < .00001), as well as a further significant decrease
between familial and sporadic breast tumors for both
Per1 (P < .00001) and Per2 (P < .00001). Decreased Per1
was also associated with estrogen receptor negativity
(53% vs 15%, P = .04). These results suggest a role for
both Per1 and Per2 in normal breast function and show
for the first time that deregulation of the circadian clock
may be an important factor in the development of
familial breast cancer. Aberrant expression of circadian
clock genes could have important consequences on
the transactivation of downstream targets that control
the cell cycle and on the ability of cells to undergo
apoptosis, potentially promoting carcinogenesis.
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Introduction
Deregulation of the circadian clock has been implicated in
many types of cancers, and large studies indicate that
increased breast cancer risk is correlated with increased
years of night shifts [1–3]. The circadian clock proteins
Per1 and Per2 function in a series of positive and negative
feedback loops that coordinate the circadian clock in both
the brain and peripheral tissues [4]. Molecularly, several
links between the circadian clock and DNA damage re-
sponse have been drawn. Mice that are deficient in the
mPer2 gene are not only deficient in their circadian clock
rhythm but also cancer-prone and sensitive to g-irradiation
[5]. Additionally, thymocytes from mPer2 mutant mice either
are less sensitive or have a slower apoptotic response to g-
irradiation [6]. Conversely, overexpression of mPer2 induces
apoptosis and alters the expression levels of apoptosis-related
genes in mouse tumor cells [7].
Moreover, overexpression of Per1 sensitizes HCT116 colon
cancer cells to infrared-induced DNA apoptosis, and suppres-
sion of Per1 blunts apoptotic response [8]. Per1 physically
interacts with ATM and Chk2, which are known to function in a
DNA damage response complex along with other components
such as BRCA1. Furthermore, Per1 expression is decreased in
small lung cell carcinoma tumors, as well as in a small cohort of
breast tumors [8].
Based on the reported involvement of the circadian clock in
the development of several cancers, including breast cancer,
as well as on experiments that have identified a putative
interaction between BRCA1 and Per1 and Per2 in a yeast
two-hybrid system, we used real-time polymerase chain reac-
tion (PCR) to examine Per1 and Per2 in both familial and
sporadic breast tumors and normal breast tissues to identify
any changes in gene expression. We observed significant
alterations in Per1 and Per2 expression suggesting that their
deregulation may contribute to the development of sporadic or
familial breast cancer, or both. Additionally, we analyzed the
associations of Per1 or Per2 with breast tumor characteris-
tics and found a significant association of Per1 expression
with estrogen receptor (ER) status. Per1 and Per2 influence
the transcription of genes and induce apoptosis; therefore, lack
or misregulation of their expression could contribute to an im-
proper apoptotic response and the development of breast cancer.
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mRNA from 34 sporadic breast tumors were obtained as
part of a prospective study of molecular alterations in auxil-
iary node–negative disease [9]. Eleven tumors were from
familial breast cancer cases from the Ontario site of the
Breast Cancer Family Registry [10].
DNA and RNA have previously been extracted by con-
ventional techniques [11]. mRNA from normal breast tissue
samples were obtained from 13 additional subjects with
‘‘sporadic’’ breast cancer. The normal breast tissue samples
were selected by a pathologist from regions adjacent to
tumors. All relevant institutional review boards approved
the study protocol, and written informed consent was
obtained from all participants.
Real-Time PCR Reactions
cDNAwas reverse-transcribed, and real-time PCRwas car-
ried out as described [12]. HPRT-1, which has little variation in
expression between tumors, was chosen for normalization.
Primer/probe pairs used for the experiments were purchased
from ABI (Foster City, CA) [BRCA1, cat no. HS 00173233-m1;
Per1, cat no. HS00242988-m1;Per2, cat no. HS002561440m1;
HPRT-1, cat no. 4326321E (endogenous control)].
Statistical Analysis
A descriptive analysis comparing the frequency distribu-
tions of tumor characteristics between the Per1 and Per2
groups (high versus low) was performed by a pathologist
using contingency tables. The association of each charac-
teristic with Per1 or Per2 expression was investigated by
Fisher’s exact test [13]. The high-versus-low levels of Per1 or
Per2 expression were established by dividing the tumor sets
around the mean level of expression of each gene.
All statistical analyses were performed using SASStatistical
Software, version 8.2 (SAS, Inc., Cary, NC). R statistical
Table 1. Summary of Gene Expression in Normal Tissues Versus Sporadic
or Familial Breast Tumors for Per1 and Per2.





Sporadic 1.8 < .00001
Familial 0.9 < .00001
Per2 Normal 4.9
Sporadic 3.6 .005
Familial 2.6 < .00001
*Test gene/HPRT-1 expression ratios as measured by quantitative real-time PCR.
Table 2. Tumor Characteristics and Association with Per1 Expression Levels (N = 33).
Characteristic Low Per1 Levels (V 1.60) High Per1 Levels (> 1.60) P * (Fisher’s Exact Test)
Number of patients [n (%)] 20 (60.6) 13 (39.4)
Age (years) {mean (SD) [minimum, maximum]} 55.2 (11.5) [35.1, 75.1] 55.2 (11.7) [37.5, 69.7]
Menopausal status [n (%)]
Premenopausal 6 (30.0) 4 (30.8) 1.00
Perimenopausal 2 (10.0) 1 (7.7)
Postmenopausal 11 (55.0) 8 (61.5)
Missing 1 (5.0) 0 (0.0)
Maximum size of tumor (cm) [n (%)]
0.5 to < 1.0 0 (0.0) 0 (0.0) .06
1.0 to < 2.0 2 (10.0) 4 (30.8)
2.0 to < 5.0 17 (85.0) 7 (53.8)
z 5.0 0 (0.0) 2 (15.4)
Missing 1 (5.0) 0 (0.0)
ER status
Positive 9 (45.0) 9 (69.2) .04
Negative 10 (50.0) 2 (15.4)
Equivocal 0 (0.0) 2 (15.4)
Unknown/not determined 0 (0.0) 0 (0.0)
Missing 1 (5.0) 0 (0.0)
Progesterone receptor status
Positive 5 (25.0) 5 (38.5) .86
Negative 12 (60.0) 7 (53.8)
Equivocal 2 (10.0) 1 (7.7)
Unknown/not determined 0 (0.0) 0 (0.0)
Missing 1 (5.0) 0 (0.0)
Histologic grade
1 1 (5.0) 1 (7.7) .90
2 6 (30.0) 5 (38.5)
3 9 (45.0) 4 (30.8)
Subtype 1 (5.0) 0 (0.0)
Unknown/not determined 2 (10.0) 3 (23.0)
Missing 1 (5.0) 0 (0.0)
Lymphatic invasion
Yes 5 (25.0) 5 (38.5) .70
No 14 (70.0) 8 (61.5)
Missing 1 (5.0) 0 (0.0)
*Without tumors in the missing category.
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software, version 1.9.1, was used to generate box plots.P < .05
was considered to be statistically significant for all analyses.
Results
Expression of Per1 and Per2 in Breast Tumors
Our preliminary results identifying the interaction of
BRCA1 with Per1 and Per2 in the yeast two-hybrid system
(data not shown) and the increasing amount of evidence that
circadian clock perturbations may result in breast cancer led
us to investigate the expression levels of BRCA1, as well as
Per1 and Per2, in both sporadic and familial primary human
breast tumors and normal breast tissues. Not surprisingly,
low levels of BRCA1 mRNA were identified in sporadic
tumors compared to both normal breast tissues and familial
cancers, consistent with decreased expression, rather than
mutation, being the means for BRCA1 inactivation in these
tumors (Table 1) [14].
Importantly, both Per1 and Per2 exhibit significantly de-
creased levels of expression in sporadic and familial tumors
compared to normal breast tissues (Table 1). Furthermore,
Per1 expression is also significantly decreased in familial
tumors compared to sporadic tumors (Table 1), suggesting
that deregulation of the circadian clock may contribute to the
familial aspect of these tumors.
Association of Per1 and Per2 with Sporadic
Tumor Characteristics
The use of primary human breast tumors allowed us
to examine correlations between tumor or disease charac-
teristics with Per1 and Per2 expression levels, and the
results for Per1 are summarized in Table 2. The group of
breast tumors with a ‘‘low’’ level of Per1 or Per2 mRNA was
compared to those with ‘‘high’’ Per1 or Per2 expression
levels, and we detected a weak association between low
Per1 expression and ER status (P = .04), which needs to be
investigated further in a larger sample set. Tumors with low
Per1 levels were more likely to be negative for ER receptor
than those with high Per1 levels (53% vs 15%). This asso-
ciation was not observed for Per2 (P = .30), and no other
significant associations were identified for Per2 (not shown).
Discussion
Deregulation of the circadian clock may lead to the develop-
ment of several types of cancer, including breast cancer.
Consequently, we performed a genetic analysis of BRCA1
and Per1 and Per2 in both sporadic and familial primary
breast tumors and normal breast tissues to identify aberra-
tions in their expression levels and to analyze whether
changes in Per1 and Per2 expression are associated with
breast tumor characteristics. Interestingly, both Per1 and
Per2 exhibit significantly decreased levels of expression in
both sporadic and familial tumors compared to normal breast
tissues. Additionally, the expression of Per1 was significantly
decreased in familial breast tumors compared to its expres-
sion in sporadic specimens, suggesting that a possible
deregulation of the circadian clock could contribute to the
familial aspect of these tumors. Our results identifying de-
creased Per1 and Per2 expression in tumors is supported by
previous work showing that Per gene deregulation is caused
by methylation of the Per1 or Per2 promoter in approximately
50% of analyzed breasts cancers in Taiwanese women [15].
Per1 and Per2 regulate transcription and promote apoptosis;
therefore, decreased levels of Per1 and Per2 in breast
tumors could have important ramifications on the expression
of both circadian and other downstream genes and could
potentially limit the apoptotic response of the cell.
The use of primary human breast tumors allowed us to
examine correlations between tumor or disease character-
istics and Per1 and Per2 expression levels. Interestingly, we
observed a statistically significant association between low
levels ofPer1 expression and negative ER status, and aweak
association between low levels ofPer1 expression and tumor
size using our small sample, which need to be investigated
further in a larger sample set. ER levels are maintained by a
number of mechanisms, including activation or repression of
the ER promoter at the transcriptional level. Interestingly,
tumors with BRCA1 mutations also tend to be negative for
ER expression [16,17], and it is possible that Per1 acts with
proteins such as BRCA1 to regulate ER transcription.
We have analyzed the expression levels of Per1 and Per2
in both sporadic and familial breast tumors, as well as in
normal breast tissues, and have determined that there are
significant decreases in Per1 and Per2 expression levels in
these tumors compared to normal breast tissues. Addition-
ally, we identified a further decrease in Per1 expression
when comparing tumors from women with familial breast
cancer to tumors from women with sporadic breast cancer,
suggesting that circadian clock disruption may contribute to
the inherited form of the disease. Furthermore, we have
detected a significant association of decreased Per1 levels
with ER-negative breast tumors. These results suggest a
role for both Per1 and Per2 in normal breast function and the
potential deregulation of Per1 and Per2 expression in breast
cancer development.
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